HomeHealthcareBiotechnology Circulating Tumor Cells (CTC) Market

Circulating Tumor Cells (CTC) Market Size, Share & Trends Analysis Report By Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, CTC Analysis), By Application (Clinical/ Liquid Biopsy, Research), By Product (Kits and Reagents, Blood Collection Tubes, Devices or Systems), By Specimen (Blood, Bone Marrow, Other Body Fluids) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 28, 2026 | Author: Debashree Bora | Format:

Circulating Tumor Cells (ctc) Market Size

The global circulating tumor cells market size was valued at USD 14.31 billion in 2025 and is projected to grow from USD 15.77 billion in 2026 to USD 34.30 billion by 2034, registering a CAGR of 10.2%. North America dominated the circulating tumor cells market with a share of 39.2% in 2025.

Circulating Tumor Cells (CTCs) are cancer cells that detach from a primary tumor or metastatic site and enter the bloodstream, potentially contributing to cancer spread to other parts of the body. Their detection and analysis help healthcare professionals assess cancer progression, monitor treatment responses, and support research into personalized cancer care.

Circulating Tumor Cells (CTC) Market Key Takeaways

Global Market Size & Growth

2025 Market Size
USD 14.31 Billion
2026 Market Size
USD 15.77 Billion
2034 Projected Market Size
USD 34.30 Billion
Forecast Period
2026–2034
Base Year
2025
Market CAGR (2026–2034)
10.2%

Regional Insights

Largest Regional Market (2025)
North America
North America Market Share (2025)
39.2%
Fastest-growing Region
Asia Pacific
Asia Pacific CAGR (2026–2034)
14.8%

Segment Insights

By Technology
Leading Segment
CTC Detection and Enrichment Methods
Market Share in 2025 46.8%
By Application
Fastest-growing Segment
Clinical/ Liquid Biopsy
CAGR (2026–2034) 13.4%
By Product
Leading Segment
Kits and Reagents
Market Share in 2025 49.6%
By Specimen
Fastest-growing Segment
Blood
CAGR (2026–2034) 13.1%
Circulating Tumor Cells (CTC) Market Size , Share and Growth Forecast 2026-2034

Download a Free SampleTo learn more about this report.

Circulating Tumor Cells (CTC) Market Dynamics

01

Metastatic Cancer Assessment and Biomarker-Based Drug Development Drive Market

The need to evaluate cancer spread and monitor disease progression supports the use of circulating tumor cell tests that detect cancer cells in blood samples. For example, oncologists may use CTC analysis to monitor metastatic breast cancer, supporting demand for specialized diagnostic tools and laboratory testing services.

Pharmaceutical research relies on cancer biomarkers to assess treatment response and identify potential targets for new therapies, supporting the use of CTC analysis in drug development. For example, researchers can study tumor cells collected from blood samples to examine treatment-related changes, creating opportunities for CTC technology providers to supply research tools and testing platforms.

01

Regulatory Approval Challenges and Low CTC Counts in Early-Stage Cancer Restrain Market Expansion

Regulatory approval challenges arise from the need to demonstrate the accuracy, reliability, and clinical value of CTC detection technologies through extensive testing and validation. Lengthy approval processes and compliance costs can delay product launches, restrict market entry, and slow adoption among healthcare providers.

Low CTC counts in early-stage cancer make tumor cells difficult to isolate and detect in blood samples, increasing the risk of false-negative results. These sensitivity limitations can reduce clinician confidence in CTC-based tests and restrict their use for early cancer detection and monitoring.

01

CTC Biobanking Services and Single-Cell Genomic Profiling Offers Growth Opportunities

Cancer research institutes, pharmaceutical companies, and biotechnology firms benefit from preserved circulating tumor cell samples for future studies and drug development. Sample storage fees, biobanking services, and research partnerships create revenue opportunities for companies such as BioIVT and Discovery Life Sciences.

Oncology researchers, diagnostic laboratories, and pharmaceutical developers benefit from genomic analysis of individual circulating tumor cells to study tumor variation and treatment response. Specialized testing services, genomic analysis platforms, and research collaborations create additional revenue avenues for companies such as 10x Genomics and Mission Bio, supporting circulating tumor cells market growth.

Circulating Tumor Cells (CTC) Market Segmentation Analysis

By Technology

CTC detection and enrichment methods held the largest market share at 46.8%. Their ability to isolate rare tumor cells from blood samples supports cancer monitoring, liquid biopsy, and treatment-response assessment.

CTC analysis is projected to grow at the highest CAGR of 14.6% during the forecast period, driven by the need for detailed cellular characterization and molecular insights into cancer progression.

Circulating Tumor Cells (CTC) Market Size By Segments

Request Customizationto receive a tailored report.

By Application

Clinical/Liquid Biopsy Projected to grow at a CAGR of 13.4% during the forecast period, supported by the use of minimally invasive testing for cancer detection, treatment selection, and disease monitoring.

Research Projected to grow at a CAGR of 11.6% during the forecast period, supported by research into tumor biology, cancer progression, and treatment-response mechanisms.

By Product

Kits and reagents held the largest market share at 49.6%, supported by their essential role in sample preparation, circulating tumor cell isolation, and laboratory analysis.

Devices or systems are projected to grow at the second-highest CAGR of 12.9% during the forecast period, driven by demand for advanced cell detection, isolation, and analysis technologies.

By Specimen

Blood held the largest market share at 78.4%. Its accessibility and suitability for minimally invasive sampling make it the primary specimen for circulating tumor cell testing.

Blood-based testing is projected to grow at a CAGR of 13.1% during the forecast period, supported by its role in liquid biopsy, serial cancer monitoring, and treatment-response evaluation.

Circulating Tumor Cells (CTC) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Circulating Tumor Cells (CTC) Market Regional Outlook

North America Circulating Tumor Cells (CTC) Market

The North America circulating tumor cells (CTC) market accounted for the largest regional share of 39.2% in 2025.

United States Circulating Tumor Cells (CTC) Market

The CDC’s 2026 Annual Report to the Nation on the Status of Cancer reported that new cancer incidence increased by approximately 0.2% annually from 2018 to 2022, while cancer death rates declined from 2019 to 2023 (CDC, October 2026). The continuing cancer burden supports the need for monitoring and precision-oncology diagnostics, including CTC analysis in appropriate clinical and research settings, although this trend does not directly predict CTC testing volumes. 

Canada Circulating Tumor Cells (CTC) Market

Cancer diagnosis and follow-up create potential demand for minimally invasive approaches that may help clinicians monitor disease progression or treatment response. However, a verified 2026 Canadian national statistic specifically measuring CTC testing volumes, adoption or expenditure was not identified, so broader cancer-incidence statistics should be treated as indirect demand indicators rather than CTC-market forecasts.

North America Circulating Tumor Cells (CTC) Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Circulating Tumor Cells (CTC) Market

The Asia-Pacific circulating tumor cells (CTC) market is expected to grow at a CAGR of 14.8% during the forecast period, making it the fastest-growing regional market.

Japan Circulating Tumor Cells (CTC) Market

A nationwide real-world analysis published in 2025 examined 7,461 patient records involving blood-based liquid-biopsy testing in Japan, using data from the Center for Cancer Genomics and Advanced Therapeutics (peer-reviewed study). The study demonstrates established use of blood-based molecular testing in precision oncology, but the tests examined were principally genomic liquid biopsies rather than direct CTC enumeration.

China Circulating Tumor Cells (CTC) Market

China’s large oncology patient population and continued development of precision medicine provide potential opportunities for CTC-based research and cancer-monitoring technologies. However, a reliable official 2026 national statistic quantifying CTC-specific clinical use, test volumes or reimbursement was not identified, so cancer burden and broader liquid-biopsy development should not be treated as direct measures of CTC demand.

India Circulating Tumor Cells (CTC) Market

India’s substantial cancer-care needs create potential demand for diagnostic technologies that can support treatment monitoring and reduce reliance on repeated invasive procedures. However, no verified official 2026 national statistic specifically measuring CTC testing volumes or adoption was identified, and broader cancer statistics alone cannot establish the size or growth rate of the Indian CTC market.

Europe Circulating Tumor Cells (CTC) Market

The Europe circulating tumor cells (CTC) market accounted for 27.4% of the global market in 2025.

United Kingdom Circulating Tumor Cells (CTC) Market

The OECD’s 2026 Delivering High-Value Cancer Care report describes liquid-biopsy-based monitoring of treatment effectiveness or relapse as an emerging application, with several European countries reporting national or regional programmes and pilots in the 2025 survey (OECD, 2026). This provides evidence of institutional interest in blood-based cancer monitoring, although adoption differs between countries and the report does not establish a UK-specific CTC testing volume.

Germany Circulating Tumor Cells (CTC) Market

Germany’s established oncology and molecular-diagnostics infrastructure provides a potential foundation for further use of blood-based monitoring technologies. The OECD’s 2026 report highlights the wider European opportunity for liquid biopsies in recurrence surveillance, but a verified 2026 German national figure specifically measuring CTC testing or spending was not identified.

Competitive Landscape

The circulating tumor cells (CTC) market is moderately fragmented, with diagnostic technology providers, biotechnology firms, life science companies, and specialized testing laboratories serving clinical and research applications.Leading players in the circulating tumor cells (CTC) market include Bio-Techne Corporation, Precision for Medicine, Inc., AVIVA Biosciences Corporation, BIOCEPT, Inc., and BioCEP Ltd., collectively accounting for an estimated 20–25% of the circulating tumor cells (CTC) market share.
 
Established players compete through detection accuracy, assay reliability, advanced technology, clinical validation, and laboratory partnerships. Emerging players in the circulating tumor cells market ecosystem focus on cost-effective testing, innovative cell isolation methods, automation, and specialized cancer research applications.

List of Key and Emerging Players in Circulating Tumor Cells (CTC) Market

QIAGEN N.V. (Netherlands)
Bio-Techne Corporation (U.S.)
Precision for Medicine, Inc. (U.S.)
AVIVA Biosciences Corporation (U.S.)
BIOCEPT, Inc. (U.S.)
BioCEP Ltd. (United Kingdom)
Fluxion Biosciences, Inc. (U.S.)
Greiner Bio-One International GmbH (Austria)
Ikonisys, Inc. (U.S.)
Miltenyi Biotec B.V. & Co. KG (Germany)
IVDiagnostics, Inc. (U.S.)
BioFluidica, Inc. (U.S.)
Canopus Bioscience Ltd. (United Kingdom)
Biolidics Limited (Singapore)
Creatv MicroTech, Inc. (U.S.)
LungLife AI, Inc. (U.S.)
Epic Sciences, Inc. (U.S.)
Rarecells Diagnostics (France)
ScreenCell (France)
Menarini Silicon Biosystems S.p.A. (Italy)
LineaRx, Inc. (U.S.)
Sysmex Corporation (Japan)
STEMCELL Technologies Canada Inc. (Canada)

Key Industry Developments

October 2026
CelLBxHealth expanded its Parsortix platform partnership with a pharmaceutical company in the United States. The collaboration supports the use of circulating tumor cell isolation and downstream analysis in pharmaceutical research and drug development.
August 2026
CelLBxHealth reported peer-reviewed research supporting the use of its Parsortix platform to isolate CTCs from blood samples of patients with glioblastoma. The study found that captured cells contained tumor-related genetic changes matching those found in tumor tissue, highlighting potential applications in minimally invasive brain cancer analysis and monitoring.
July 2026
Cancer Cell Diagnostics launched its CellSight DNA genomic profiling test, which isolates intact CTCs from blood samples and analyzes more than 500 genes. The platform is designed to identify genomic alterations and other tumor characteristics, with potential for further whole-cell molecular analysis.
January 2026
Menarini Silicon Biosystems expanded its circulating tumor cell analysis portfolio with advancements in liquid biopsy technologies designed to improve cancer biomarker detection, treatment monitoring, and precision oncology research.

Report Scope

Segmentation

By Technology 3
  • CTC Detection and Enrichment Methods
  • CTC Direct Detection Methods
  • CTC Analysis
By Application 2
  • Clinical/ Liquid Biopsy
  • Research
By Product 3
  • Kits and Reagents
  • Blood Collection Tubes
  • Devices or Systems
By Specimen 3
  • Blood
  • Bone Marrow
  • Other Body Fluids

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage QIAGEN N.V. (Netherlands) · Bio-Techne Corporation (U.S.) · Precision for Medicine, Inc. (U.S.) · AVIVA Biosciences Corporation (U.S.) · BIOCEPT, Inc. (U.S.)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Reportto Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The circulating tumor cells market size is valued at USD 15.77 Billion in 2026 and is projected to reach USD 34.30 Billion by 2034, at a CAGR of 10.2% during the forecast period 2026-2034.
North America dominated the market with a share of 39.2% in 2025.
The leading players in this market are QIAGEN, Bio-Techne Corporation, Precision for Medicine, AVIVA Biosciences, BIOCEPT.
The circulating tumor cells market is projected to grow at a CAGR of 10.2% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG ElectronicsAMCAD EngineeringKOBE STEEL LTD.Hindustan National Glass & Industries LimitedVoith GroupInternational PaperHansol PaperWhirlpool CorporationSonySamsung ElectronicsQualcommGoogleFiservVeto-PharmaNippon Becton DickinsonMerckArgon Medical DevicesAbbottAjinomotoDenonDoosanMeiji Seika Kaisha LtdLG ChemicalsLCY chemical groupBayerAirraneBASFToyota IndustriesNissan MotorsNeenahMitsubishiHyundai Motor CompanyHondaCRP Industries IncpewagLGEPanasonicLubrizol CorporationLeonardoJohnson & JohnsonHB FullerMITSUBISHI CHEMICALHyundai MobisAmazon
Request SampleOrder Report Now